This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clonidine in the treatment of menopausal symptoms

Authoring team

  • there is evidence that clonidine improves the symptoms of menopausal hot flushes in approximately 40% of women (1)



    (3)
    • clonidine is often used as a first-line treatment in a dose of two or three 25μg tablets twice daily (2)

    • a maximum of 75 micrograms bd or 50mcg tds should be used (3)

    • however side effect with clonidine treatment are common and include dizziness, irritability, nausea and dry mouth
    • interaction with anti-hypertensive drugs and not suitable for patients with baseline low blood pressure
    • must be reduced gradually otherwise causes rebound hypertension (3)

    • dose related side-effects include sleep disturbance in at least 50% of patients, dry mouth nausea and fatigue

The summary of drug characteristics should be consulted before prescribing this drug.

Reference:

  1. Laufer LR et al (1982). Effect of clonidine on hot flushes in postmenopausal women. Obstet Gynecol, 60, 583-6.
  2. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006;355(22):2338-47.
  3. British Menopause Society. Prescribable alternatives to HRT (Accessed 12/2/2020).
  4. Prescriber (2001), 12, 13 (5), 47-58.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.